Daniel Junius to Retire as President and CEO of ImmunoGen, Inc.
05 April 2016 - 10:00PM
Business Wire
– Successor Expected to be Announced
Shortly –
ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company that
develops targeted anticancer therapeutics using its antibody-drug
conjugate (ADC) technology, today announced that Daniel Junius, age
63, has decided to retire from his positions of President and CEO
of the Company. This will become effective when his successor joins
ImmunoGen. Mr. Junius has been the Company’s CEO since January
2009. Following his retirement, Mr. Junius will continue to serve
on ImmunoGen’s Board of Directors.
In September 2015, Mr. Junius discussed with ImmunoGen’s Board
that he was considering retiring by the end of the Company’s fiscal
year in June if an appropriate successor could be found within that
timeframe. The Board then formed a search committee, retained an
executive recruitment firm, and began formal succession planning.
It is currently anticipated that a successor to Mr. Junius will be
announced shortly.
“Dan has taken ImmunoGen from being a research company with a
validated technology to one with strong research, development,
clinical and manufacturing functions that is advancing a rich
pipeline of product candidates driven by an expanding technology
portfolio,” commented Stephen McCluski, Chairman of the Board. “The
Board is grateful to Dan for his extensive contributions to
ImmunoGen and his commitment to making a difference for patients
with cancer.”
“For over seven years, I have had the privilege of leading a
company full of smart, team-oriented employees committed to
developing better treatments for cancer,” noted Mr. Junius. “I
believe ImmunoGen is in a strong position today and look forward to
its continued advancement under the next CEO.”
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that
develops targeted anticancer therapeutics using its proprietary ADC
technology. The Company’s lead product candidate, mirvetuximab
soravtansine, is in Phase 2 testing for the treatment of folate
receptor α-positive ovarian cancer. ImmunoGen's ADC technology is
used in Roche's marketed product, Kadcyla®, and in programs in
development by partners Amgen, Bayer, Biotest, CytomX, Lilly,
Novartis, Sanofi and Takeda. More information about the Company can
be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160405005301/en/
For Investors:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.comorFor Media:Michael Lampe,
484-575-5040michael@michaellampeconsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2024 to May 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From May 2023 to May 2024